(PresseBox) (Schlieren (Zurich), ) Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announces today the appointment of Dr. Patrick Vink as Chairman of the Board of Directors. Dr. Vink replaces Mr. Harry Welten, who joined the Biognosys Board in 2011 and became Chairman in 2015.
Dr. Vink has an M.D. from the University of Leiden and an MBA from the University of Rochester. He brings over 25 years of experience in the life sciences industry, with a strong track record in building and growing global biotechnology and pharmaceutical businesses. He was previously Chief Operating Officer at Cubist Pharmaceuticals Inc, overseeing all worldwide commercial and technical operations as well as global alliance management. Prior to Cubist, he was Head of the Global Hospital Business and executive team member at Mylan Inc., Head of Global Biopharmaceuticals at Sandoz (a division of Novartis), and held various senior positions at Biogen Inc, Sanofi-Synthelabo, and Numico.
Dr. Vink is currently on the board of several U.S. and European publicly listed and private companies, including as Chairman of F2G and NMD Pharma and Board Member at Amryt Pharma, Santhera Pharmaceuticals and Spero Therapeutics.
As Chairman of Biognosys, Dr. Vink will support the company’s strategic expansion into proteomics for large-scale applications across the drug development value chain.
Dr. Oliver Rinner, CEO of Biognosys, says: “I am delighted to welcome Dr. Vink as our Chairman now that we are realizing our next stage of growth following the completion of our latest Financing Round. I would also like to thank our prior Chairman, Harry Welten, for his many years of service to our board, guiding the company from its start-up phase to an established leader in proteomics services and products.”
Dr. Patrick Vink, Chairman of Biognosys, commented: “I am excited to join Biognosys at a time when proteomics is increasingly established to support drug research and development.”
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science research by making the most advanced proteomics tools available to researchers. The company offers a suite of products and services to decode the proteome and equip researchers from all fields with a deep view of protein expression in cells, tissues, or body fluids. Biognosys’ technology is based on high-resolution mass spectrometry, combined with a novel parallel signal processing approach, for unprecedented quantification of large proteomes in a single experiment. More information at: www.biognosys.com
Oliver Rinner, PhD
Chief Executive Officer
Phone +41 (0) 44 738 20 40
Mobile +41 (0) 78 664 47 11
Please find the official press release here (English).
Access our knowledge base with relevant resources and guiding information.